Study of the Effects of an Investigational Drug or Combination of Drugs Compared to Standard Therapy to Treat Cancer of the Head and Neck

What we are studying

You have been asked to take part in this study because you have a type of head and neck cancer which is called Squamous Cell Carcinoma of the Head and Neck (SCCHN). Your cancer has either returned or has spread to other parts of your body (either recurrent or metastatic). This study is being carried out to see if experimental anti-cancer medicines called MEDI4736 and MEDI4736 + tremelimumab are effective in treating the type of cancer that you have compared to standard, approved treatment.

Who we are studying

  • Men and Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18+

Eligibility Criteria

  • Informed consent
  • Tumor progression or recurrence during or after treatment with platinum containing therapy
  • Measurable tumor that was not previously exposed to radiation treatment
  • Adequate organ and marrow function
  • Non-Pregnant or nursing.

What is involved

  • Comprehensive physical exams and vitals at each visit
  • Concomitant medication history
  • HPV status determination
  • Medical surgical history
  • Tobacco use history
  • Blood draws
  • Tumor biopsy
  • CT or MRI every 8 weeks for the 1st 48 weeks and then every 12 weeks after treatment discontinuation
  • Ecgs
  • Questionnaires
  • IV administration of study drug as frequently as every 2 weeks


A stipend will be provided to assist with parking and travel related to study visits.

Contact Information

Study Coordinator
Sharon Averill
Principal Investigator
Marcelo Bonomi, MD

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.